ARTICLE | Analyst Picks & Changes
Analyst picks & changes
January 3, 1995 8:00 AM UTC
UBS Securities analyst Marc Ostro said that changes in the Phase III protocol of Alpha-Beta Technology Inc.'s Betafectin anti-infective in high-risk abdominal surgery patients, as a result of the FDA's review, will change the statistical power of the trial in favor of the drug. ...